BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Celikbilek M, Baskol M, Taheri S, Deniz K, Dogan S, Zararsiz G, Gursoy S, Guven K, Ozbakır O, Dundar M, Yucesoy M. Circulating microRNAs in patients with non-alcoholic fatty liver disease. World J Hepatol 2014; 6(8): 613-620 [PMID: 25232454 DOI: 10.4254/wjh.v6.i8.613] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 46] [Article Influence: 5.9] [Reference Citation Analysis]
Number Citing Articles
1 Lee J, Kim Y, Friso S, Choi SW. Epigenetics in non-alcoholic fatty liver disease. Mol Aspects Med. 2016; Nov 23. [Epub ahead of print]. [PMID: 27889327 DOI: 10.1016/j.mam.2016.11.008] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 9.7] [Reference Citation Analysis]
2 Lai CY, Lin CY, Hsu CC, Yeh KY, Her GM. Liver-directed microRNA-7a depletion induces nonalcoholic fatty liver disease by stabilizing YY1-mediated lipogenic pathways in zebrafish. Biochim Biophys Acta Mol Cell Biol Lipids 2018;1863:844-56. [PMID: 29678641 DOI: 10.1016/j.bbalip.2018.04.009] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
3 Liu XL, Cao HX, Fan JG. MicroRNAs as biomarkers and regulators of nonalcoholic fatty liver disease. J Dig Dis. 2016;17:708-715. [PMID: 27628945 DOI: 10.1111/1751-2980.12408] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
4 Turchinovich A, Baranova A, Drapkina O, Tonevitsky A. Cell-Free Circulating Nucleic Acids as Early Biomarkers for NAFLD and NAFLD-Associated Disorders. Front Physiol 2018;9:1256. [PMID: 30294278 DOI: 10.3389/fphys.2018.01256] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
5 Liu XL, Pan Q, Zhang RN, Shen F, Yan SY, Sun C, Xu ZJ, Chen YW, Fan JG. Disease-specific miR-34a as diagnostic marker of non-alcoholic steatohepatitis in a Chinese population. World J Gastroenterol 2016; 22(44): 9844-9852 [PMID: 27956809 DOI: 10.3748/wjg.v22.i44.9844] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 40] [Article Influence: 7.7] [Reference Citation Analysis]
6 Torres JL, Novo-Veleiro I, Manzanedo L, Alvela-Suárez L, Macías R, Laso FJ, Marcos M. Role of microRNAs in alcohol-induced liver disorders and non-alcoholic fatty liver disease. World J Gastroenterol 2018; 24(36): 4104-4118 [PMID: 30271077 DOI: 10.3748/wjg.v24.i36.4104] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 33] [Article Influence: 8.8] [Reference Citation Analysis]
7 Mentzel CM, Alkan F, Keinicke H, Jacobsen MJ, Gorodkin J, Fredholm M, Cirera S. Joint Profiling of miRNAs and mRNAs Reveals miRNA Mediated Gene Regulation in the Göttingen Minipig Obesity Model. PLoS One 2016;11:e0167285. [PMID: 27902747 DOI: 10.1371/journal.pone.0167285] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
8 Sun C, Fan JG, Qiao L. Potential epigenetic mechanism in non-alcoholic Fatty liver disease. Int J Mol Sci. 2015;16:5161-5179. [PMID: 25751727 DOI: 10.3390/ijms16035161] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 7.6] [Reference Citation Analysis]
9 Zhu B, Chan SL, Li J, Li K, Wu H, Cui K, Chen H. Non-alcoholic Steatohepatitis Pathogenesis, Diagnosis, and Treatment. Front Cardiovasc Med 2021;8:742382. [PMID: 34557535 DOI: 10.3389/fcvm.2021.742382] [Reference Citation Analysis]
10 Schuster S, Cabrera D, Arrese M, Feldstein AE. Triggering and resolution of inflammation in NASH. Nat Rev Gastroenterol Hepatol. 2018;15:349-364. [PMID: 29740166 DOI: 10.1038/s41575-018-0009-6] [Cited by in Crossref: 197] [Cited by in F6Publishing: 196] [Article Influence: 65.7] [Reference Citation Analysis]
11 Guo Y, Xiong Y, Sheng Q, Zhao S, Wattacheril J, Flynn CR. A micro-RNA expression signature for human NAFLD progression. J Gastroenterol. 2016;51:1022-1030. [PMID: 26874844 DOI: 10.1007/s00535-016-1178-0] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 7.8] [Reference Citation Analysis]
12 He Z, Hu C, Jia W. miRNAs in non-alcoholic fatty liver disease. Front Med. 2016;10:389-396. [PMID: 27680976 DOI: 10.1007/s11684-016-0468-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
13 Zhang C, Wang P, Li Y, Huang C, Ni W, Chen Y, Shi J, Chen G, Hu X, Ye M, Duan S, Wang K. Role of MicroRNAs in the Development of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Anat Rec (Hoboken) 2019;302:193-200. [PMID: 30312023 DOI: 10.1002/ar.23954] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
14 Gallego-Durán R, Romero-Gómez M. Epigenetic mechanisms in non-alcoholic fatty liver disease: An emerging field. World J Hepatol 2015; 7(24): 2497-2502 [PMID: 26523202 DOI: 10.4254/wjh.v7.i24.2497] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 3.7] [Reference Citation Analysis]
15 Newman LA, Sorich MJ, Rowland A. Role of Extracellular Vesicles in the Pathophysiology, Diagnosis and Tracking of Non-Alcoholic Fatty Liver Disease. J Clin Med 2020;9:E2032. [PMID: 32610455 DOI: 10.3390/jcm9072032] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
16 Liu CH, Ampuero J, Gil-Gómez A, Montero-Vallejo R, Rojas Á, Muñoz-Hernández R, Gallego-Durán R, Romero-Gómez M. miRNAs in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. J Hepatol 2018;69:1335-48. [PMID: 30142428 DOI: 10.1016/j.jhep.2018.08.008] [Cited by in Crossref: 44] [Cited by in F6Publishing: 50] [Article Influence: 11.0] [Reference Citation Analysis]
17 Zarfeshani A, Ngo S, Sheppard AM. MicroRNA Expression Relating to Dietary-Induced Liver Steatosis and NASH. J Clin Med. 2015;4:1938-1950. [PMID: 26580662 DOI: 10.3390/jcm4111938] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
18 Piccinin E, Arconzo M, Graziano G, Vacca M, Peres C, Bellafante E, Villani G, Moschetta A. Hepatic microRNA Expression by PGC-1α and PGC-1β in the Mouse. Int J Mol Sci 2019;20:E5735. [PMID: 31731670 DOI: 10.3390/ijms20225735] [Reference Citation Analysis]
19 Huang R, Duan X, Fan J, Li G, Wang B. Role of Noncoding RNA in Development of Nonalcoholic Fatty Liver Disease. Biomed Res Int 2019;2019:8690592. [PMID: 30931332 DOI: 10.1155/2019/8690592] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
20 Raitoharju E, Seppälä I, Lyytikäinen LP, Viikari J, Ala-Korpela M, Soininen P, Kangas AJ, Waldenberger M, Klopp N, Illig T, Leiviskä J, Loo BM, Oksala N, Kähönen M, Hutri-Kähönen N, Laaksonen R, Raitakari O, Lehtimäki T. Blood hsa-miR-122-5p and hsa-miR-885-5p levels associate with fatty liver and related lipoprotein metabolism-The Young Finns Study. Sci Rep 2016;6:38262. [PMID: 27917915 DOI: 10.1038/srep38262] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 6.0] [Reference Citation Analysis]
21 Willeit P, Skroblin P, Kiechl S, Fernández-Hernando C, Mayr M. Liver microRNAs: potential mediators and biomarkers for metabolic and cardiovascular disease? Eur Heart J 2016;37:3260-6. [PMID: 27099265 DOI: 10.1093/eurheartj/ehw146] [Cited by in Crossref: 67] [Cited by in F6Publishing: 63] [Article Influence: 11.2] [Reference Citation Analysis]
22 Cai C, Lin Y, Yu C. Circulating miRNAs as Novel Diagnostic Biomarkers in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Can J Gastroenterol Hepatol 2019;2019:2096161. [PMID: 31531307 DOI: 10.1155/2019/2096161] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
23 Zhang X, Asllanaj E, Amiri M, Portilla-Fernandez E, Bramer WM, Nano J, Voortman T, Pan Q, Ghanbari M. Deciphering the role of epigenetic modifications in fatty liver disease: A systematic review. Eur J Clin Invest 2021;51:e13479. [PMID: 33350463 DOI: 10.1111/eci.13479] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Pant K, Venugopal SK. Circulating microRNAs: Possible role as non-invasive diagnostic biomarkers in liver disease. Clinics and Research in Hepatology and Gastroenterology 2017;41:370-7. [DOI: 10.1016/j.clinre.2016.11.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
25 López-Riera M, Conde I, Quintas G, Pedrola L, Zaragoza Á, Perez-Rojas J, Salcedo M, Benlloch S, Castell JV, Jover R. Non-invasive prediction of NAFLD severity: a comprehensive, independent validation of previously postulated serum microRNA biomarkers. Sci Rep 2018;8:10606. [PMID: 30006517 DOI: 10.1038/s41598-018-28854-4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 7.3] [Reference Citation Analysis]
26 Broermann A, Schmid R, Gabrielyan O, Sakowski M, Eisele C, Keller S, Wolff M, Baum P, Stierstorfer B, Huber J, Krämer BK, Hocher B, Streicher R, Delić D. Exosomal miRNAs as Potential Biomarkers to Monitor Phosphodiesterase 5 Inhibitor Induced Anti-Fibrotic Effects on CCl4 Treated Rats. Int J Mol Sci 2020;22:E382. [PMID: 33396535 DOI: 10.3390/ijms22010382] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
27 Zarrinpar A, Gupta S, Maurya MR, Subramaniam S, Loomba R. Serum microRNAs explain discordance of non-alcoholic fatty liver disease in monozygotic and dizygotic twins: a prospective study. Gut. 2016;65:1546-1554. [PMID: 26002934 DOI: 10.1136/gutjnl-2015-309456] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 7.0] [Reference Citation Analysis]
28 Micó V, Díez-Ricote L, Daimiel L. Nutrigenetics and Nutrimiromics of the Circadian System: The Time for Human Health. Int J Mol Sci 2016;17:299. [PMID: 26927084 DOI: 10.3390/ijms17030299] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
29 Zhu M, Wang Q, Zhou W, Liu T, Yang L, Zheng P, Zhang L, Ji G. Integrated analysis of hepatic mRNA and miRNA profiles identified molecular networks and potential biomarkers of NAFLD. Sci Rep 2018;8:7628. [PMID: 29769539 DOI: 10.1038/s41598-018-25743-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
30 Dongiovanni P, Meroni M, Longo M, Fargion S, Fracanzani AL. miRNA Signature in NAFLD: A Turning Point for a Non-Invasive Diagnosis. Int J Mol Sci 2018;19:E3966. [PMID: 30544653 DOI: 10.3390/ijms19123966] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 11.5] [Reference Citation Analysis]
31 Sulaiman SA, Muhsin NIA, Jamal R. Regulatory Non-coding RNAs Network in Non-alcoholic Fatty Liver Disease. Front Physiol 2019;10:279. [PMID: 30941061 DOI: 10.3389/fphys.2019.00279] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 9.0] [Reference Citation Analysis]
32 Veshkini A, Mohammadi-Sangcheshmeh A, Alamouti AA, Kouhkan F, Salehi A. Maternal supplementation with fish oil modulates inflammation-related MicroRNAs and genes in suckling lambs. Trop Anim Health Prod 2020;52:1561-72. [PMID: 31820306 DOI: 10.1007/s11250-019-02157-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
33 Borges E Jr, Mulato MGF, Souza A Setti, Iaconelli A Jr, Vieira M Geraldo, Paes D de Almeida Ferreira Braga. Serum microRNA profiling for the identification of predictive molecular markers of the response to controlled ovarian stimulation. JBRA Assist Reprod 2020;24:97-103. [PMID: 31693318 DOI: 10.5935/1518-0557.20190070] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 Zhao F. Dysregulated Epigenetic Modifications in the Pathogenesis of NAFLD-HCC. In: Yu J, editor. Obesity, Fatty Liver and Liver Cancer. Singapore: Springer; 2018. pp. 79-93. [DOI: 10.1007/978-981-10-8684-7_7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
35 DiStefano JK, Gerhard GS. Circulating microRNAs in nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol. 2016;10:161-163. [PMID: 26606259 DOI: 10.1586/17474124.2016.1125290] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
36 Lin HY, Yang YL, Wang PW, Wang FS, Huang YH. The Emerging Role of MicroRNAs in NAFLD: Highlight of MicroRNA-29a in Modulating Oxidative Stress, Inflammation, and Beyond. Cells 2020;9:E1041. [PMID: 32331364 DOI: 10.3390/cells9041041] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
37 Nie J, Li CP. Mechanisms of microRNAs in regulation of apoptosis in non-alcoholic fatty liver disease. Shijie Huaren Xiaohua Zazhi 2015; 23(15): 2389-2396 [DOI: 10.11569/wcjd.v23.i15.2389] [Reference Citation Analysis]
38 Di Mauro S, Scamporrino A, Filippello A, Di Pino A, Scicali R, Malaguarnera R, Purrello F, Piro S. Clinical and Molecular Biomarkers for Diagnosis and Staging of NAFLD. Int J Mol Sci 2021;22:11905. [PMID: 34769333 DOI: 10.3390/ijms222111905] [Reference Citation Analysis]
39 Ye JH, Chao J, Chang ML, Peng WH, Cheng HY, Liao JW, Pao LH. Pentoxifylline ameliorates non-alcoholic fatty liver disease in hyperglycaemic and dyslipidaemic mice by upregulating fatty acid β-oxidation. Sci Rep 2016;6:33102. [PMID: 27612024 DOI: 10.1038/srep33102] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
40 Liu J, Xiao Y, Wu X, Jiang L, Yang S, Ding Z, Fang Z, Hua H, Kirby MS, Shou J. A circulating microRNA signature as noninvasive diagnostic and prognostic biomarkers for nonalcoholic steatohepatitis. BMC Genomics 2018;19:188. [PMID: 29523084 DOI: 10.1186/s12864-018-4575-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
41 Xin S, Zhan Q, Chen X, Xu J, Yu Y. Efficacy of serum miRNA test as a non-invasive method to diagnose nonalcoholic steatohepatitis: a systematic review and meta-analysis. BMC Gastroenterol 2020;20:186. [PMID: 32532204 DOI: 10.1186/s12876-020-01334-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
42 Afonso MB, Rodrigues PM, Simão AL, Castro RE. Circulating microRNAs as Potential Biomarkers in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma. J Clin Med 2016;5:E30. [PMID: 26950158 DOI: 10.3390/jcm5030030] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 8.5] [Reference Citation Analysis]
43 Santhekadur PK, Kumar DP. RISC assembly and post-transcriptional gene regulation in Hepatocellular Carcinoma. Genes Dis 2020;7:199-204. [PMID: 32215289 DOI: 10.1016/j.gendis.2019.09.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
44 Hendy OM, Rabie H, El Fouly A, Abdel-Samiee M, Abdelmotelb N, Elshormilisy AA, Allam M, Ali ST, Bahaa El-Deen NM, Abdelsattar S, Mohamed SM. The Circulating Micro-RNAs (-122, -34a and -99a) as Predictive Biomarkers for Non-Alcoholic Fatty Liver Diseases. Diabetes Metab Syndr Obes 2019;12:2715-23. [PMID: 31908512 DOI: 10.2147/DMSO.S231321] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
45 Gjorgjieva M, Sobolewski C, Dolicka D, Correia de Sousa M, Foti M. miRNAs and NAFLD: from pathophysiology to therapy. Gut 2019;68:2065-79. [PMID: 31300518 DOI: 10.1136/gutjnl-2018-318146] [Cited by in Crossref: 41] [Cited by in F6Publishing: 45] [Article Influence: 13.7] [Reference Citation Analysis]
46 Wang DD, Chen X, Yu DD, Yang SJ, Shen HY, Sha HH, Zhong SL, Zhao JH, Tang JH. miR-197: A novel biomarker for cancers. Gene 2016;591:313-9. [PMID: 27320730 DOI: 10.1016/j.gene.2016.06.035] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
47 Yu Y, Zhu J, Liu J, Huang M, Wan JX. Identification of 8-miRNAs as biomarkers for nonalcoholic fatty liver disease. J Cell Physiol 2019;234:17361-9. [PMID: 30790285 DOI: 10.1002/jcp.28356] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]